Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel Finds Animal Models Predict Human Response To HGS Anthrax Drug

Executive Summary

Animal model results for Human Genome Sciences' raxibacumab are predictive of the biologics' ability to treat inhalation anthrax in humans, FDA's Anti-Infective Drugs Advisory Committee concluded Oct. 27, but FDA should request more evidence on whether the monoclonal antibody adds benefit to treatment with antibiotics alone
Advertisement

Related Content

FDA Advisory Cmte. Loosens Statistical Significance Standard, Waves GSK’s Anthrax Drug Through
GSK’s Anthrax Treatment Raxibacumab Gets Second Chance To Be First Animal Rule NME
Animal Rule's Study Designs For Anthrax Vaccine Show Utility For Other Products
Animal Rule's Study Designs For Anthrax Vaccine Show Utility For Other Products
FDA Moving Beyond Animal Rule To Animal Guidance With November Workshop
Carbaglu Does Not Set Precedent For Orphan Drugs To Skip Trials, FDA Says
FDA Advisory Committee To Review Human Genome Sciences' Anthrax Treatment
Smallpox Drug Development May Get Boost From FDA
FDA Animal Efficacy Rule Drops Superiority Requirement For New Agents
FDA Animal Efficacy Rule Drops Superiority Requirement For New Agents

Topics

Advertisement
UsernamePublicRestriction

Register

PS051625

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel